

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

\_\_\_\_\_  
Type or print name of person signing certification

\_\_\_\_\_  
Signature

\_\_\_\_\_  
Date

**PATENT**  
**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

U. S. Patent No. : US 7,282,595  
Issued: : October 16, 2007  
First Applicant : MADER, Mary Margaret  
Serial No. : 10/535,002  
Application Date : November 13, 2003  
US Nat'l Entry Date : May 12, 2005  
(if applicable):  
Entitled : ANTITUMOR BENZOYLSULFONAMIDES  
Docket No. : X-16114

**REQUEST FOR CERTIFICATE OF CORRECTION**  
**UNDER 37 C.F.R. 1.322**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The patentee of the above-identified patent respectfully requests that you issue a Certificate of Correction to correct errors which occurred during the printing of the patent. Attached is a copy of Form PTO 1050 on which the errors are specified.

Respectfully submitted,

/Tina M. Tucker/  
Tina M. Tucker  
Attorney for Applicants  
Registration No. 47,145  
Phone: 317-277-3537

Eli Lilly and Company  
Patent Division  
P.O. Box 6288  
Indianapolis, Indiana 46206-6288  
June 25, 2010

---

UNITED STATES PATENT AND TRADEMARK OFFICE  
CERTIFICATE OF CORRECTION

Page 1 of 1

PATENT NO. : US 7,282,595  
APPLICATION NO. : 10/535,002  
ISSUE DATE : October 16, 2007  
INVENTOR(S) : MADER Mary Margaret, et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

The priority date (November 22, 2002) was not printed on the front page of the above-referenced patent although the record reflects that the priority was reported to the USPTO. For your convenience, we have attached a copy of the Transmittal Letter (dated May 12, 2005) to this Certificate.

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Eli Lilly and Company

P. O. Box 6288

Indianapolis, IN 46206-6288

~~This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 422 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.~~

IN THE UNITED STATES RECEIVING OFFICE (USRO)

Applicant(s): Mary Margaret MADER, Luisa MARTIN, and Michael Enrico RICHETT

International Application No.: PCT/US2003/035041

Filed: 13 November 2003 (13.11.2003)

Invention: ANTITUMOR BENZOYLSULFONAMIDES

Lilly Reference: X16114

Earliest Priority Date: 22 November 2002 (22.11.2002)

Certificate Under 37 C.F.R. § 1.10

Attention: DO/EO

Mail Stop PCT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

EV393130848US

Sir/Madam:

"Express Mail" mailing label number: EV 393130848 US

Date of Deposit: 12 May 2005

I hereby certify that the following attached paper or fee

Transmittal Letter to the United States Designated/Elected Office (US) concerning a filing under 35 U.S.C. 371 of the International Application identified above is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

BUEEN Thomas

(Typed or printed name of person mailing paper)

Queen Thomas

(Signature of person mailing paper or fee)

**TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. 371**

INTERNATIONAL APPLICATION NO.

**PCT/US2003/035041**

INTERNATIONAL FILING  
DATE

**13 November 2003  
(13.11.2003)**

PRIORITY DATE CLAIMED

**22 November 2002 (22.11.2002)**

**TITLE OF INVENTION: ANTITUMOR BENZOYL SULFONAMIDES**

**APPLICANT(S) FOR DO/EO/US: Mary Margaret MADER, Luisa MARTIN, and Michael Enrico RICHTT**

Applicant herewith submits to the U.S. Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
  - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☐ has been transmitted by the International Bureau.
  - c. ☒ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
  - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☐ have been transmitted by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☒ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☒ A declaration of the inventors 35 U.S.C. 371(c)(4) was provided in the PCT Request Form.
11. ☒ A copy of the International Preliminary Examination Report (IPER), including any annexes, and, if not in English, an English language translation of the annexes to the IPER under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 12. to 18. below concern document(s) or information included:

12. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
13. ☒ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
14. ☐ Assignment has been recorded at reel \_\_\_\_\_, frame \_\_\_\_\_.
15. ☐ A FIRST preliminary amendment.
16. ☐ A SECOND or SUBSEQUENT preliminary amendment.
17. ☒ A Sequence Listing, 1.821 Statement, and diskette.
18. ☒ A power of attorney with attachments.
19. ☒ Other items or information:

Please amend the first page of the specification by inserting the following cross-reference after the title:

"This is the national phase application, under 35 USC 371, for PCT/US2003/035041, filed 13 November 2003, which, claims the benefit, under 35 USC 119(e), of US provisional application 60/428,891, filed 22 November 2002."

U.S. APPLICATION NO. (if known, see 37 C.F.R. 1.5) <div style="border: 1px solid black; padding: 2px; text-align: center;"> <b>PCT/US2003/035041</b> </div>	INTERNATIONAL APPLICATION NO. <div style="border: 1px solid black; padding: 2px; text-align: center;"> <b>PCT/US2003/035041</b> </div>	ATTORNEY'S DOCKET NUMBER <div style="border: 1px solid black; padding: 2px; text-align: center;"> <b>X16114</b> </div>
19. <input checked="" type="checkbox"/> The following fees are submitted: Basic National Stage Fee = <span style="float: right;"><b>\$ 300.00</b></span>  National Stage Search Fee = <span style="float: right;"><b>\$ 500.00</b></span>  National Stage Examination Fee = <span style="float: right;"><b>\$ 200.00</b></span> <b>TOTAL NATIONAL STAGE FEES</b> <span style="float: right;"><b>\$1,000.00 (a)</b></span>  Application Length Fee  Total Length (excluding sequence listings)  <div style="text-align: center;"><b>27 - 100 = 0 excess pages (b)</b></div> No extra charge for first 100 pages. Must pay \$250 for each addl 50 pages (or fraction thereof).		<div style="border: 1px solid black; padding: 2px;"> <b>CALCULATIONS    PTO USE ONLY</b> </div>
<b>ENTER APPROPRIATE AMOUNT (a + b) =</b>		<b>\$1,000.00</b>
Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492(e)).		\$
CLAIMS	NUMBER FILED	NUMBER EXTRA
Total claims	5-20=	X \$50.00
Independent claims	3-3=	X \$200.00
MULTIPLE DEPENDENT CLAIM(S) (if applicable)		+ \$360.00
<b>TOTAL OF ABOVE CALCULATIONS =</b>		\$ 0.00
Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).		\$
<b>SUBTOTAL =</b>		\$1,000.00
Processing fee of \$130.00 for furnishing English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).		\$
<b>TOTAL NATIONAL FEE =</b>		\$1,000.00
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31).		\$
<b>\$40.00 per property</b>		
<b>TOTAL FEES ENCLOSED =</b>		\$1,000.00
		Amount to be refunded
		charged
a. <input type="checkbox"/> A check in the amount of \$ _____ to cover the above fees is enclosed. b. <input checked="" type="checkbox"/> Please charge my Deposit Account No. 05-0840 in the amount of <u>\$1,000.00</u> to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 05-0840. A duplicate copy of this sheet is enclosed.		
<b>NOTE:</b> Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.		
SEND ALL CORRESPONDENCE TO: ELI LILLY AND COMPANY PATENT DIVISION P.O. BOX 6288 INDIANAPOLIS, INDIANA 46206-6288 <div style="text-align: right;"> </div>		
<div style="border: 1px solid black; padding: 10px; margin: 0 auto; width: 80%;">               SIGNATURE               Tina M. Tucker               (317) 277-3537              TELEPHONE NUMBER           </div>		
<div style="border: 1px solid black; padding: 10px; margin: 0 auto; width: 80%;"> <div style="display: flex; justify-content: space-between; align-items: center;"> <div>             11 May 2003              Date              47.145           </div> <div style="text-align: right;"> <b>25885</b>              PATENT TRADEMARK OFFICE           </div> </div> </div>		
REGISTRATION NUMBER _____		